Janssen Pharmaceuticals has obtained worldwide rights – excluding China and Korea – to develop and commercialise oxyntomodulin-based therapies including HM12525A, a biologic that is completing phase 1 and expected to enter phase 2 studies next year, from Hanmi.
HM12525A is an oxyntomodulin-based therapy that has shown evidence of improving multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity. This asset has the potential, as a once weekly therapy, to be a best-in class oxyntomodulin-based therapy.
“We are very excited about this agreement with Hanmi and the potential of HM12525A to improve therapeutic options for people living with metabolic diseases,” said James List, M.D., Ph.D., global therapeutic head, cardiovascular & metabolism, Janssen.
He adds: “Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases.”
The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
